Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System

Overview of attention for article published in Frontiers in Pharmacology, June 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (58th percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 37 Dimensions

Readers on

mendeley: 30 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 7,185 followers.

RT @jordimontana: "254,886 AEs induced by secukinumab were identified. Secukinumab-induced AE occurrence targeted 27 system organ classes (…

03 Jul 2022

Reply Repost Favourite

"254,886 AEs induced by secukinumab were identified. Secukinumab-induced AE occurrence targeted 27 system organ classes (SOCs)" https://t.co/kGfIFdXpFS

02 Jul 2022

Reply Repost Favourite

New Research: Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System https://t.co/cO2JQdLnyV #pharmacology

08 Jun 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.